All In Biotech

Drug Trial Radar · NCT03818828

Subjects With Non-Healing Venous Leg Ulcers Treated With Standard Care Plus Cryopreserved Human Umbilical Cord (TTAX01)

A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Non-Healing Venous Leg Ulcers Treated With Standard Care Plus Cryopreserved Human Umbilical Cord (TTAX01)

Last checked: Nov 20, 2026Latest source record: Sep 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

31

Actual

Start

Feb 14, 2019

Primary completion

Dec 20, 2019

Study completion Jan 28, 2020

Sponsor

Lead sponsor
BioTissue Holdings, IncIndustry
Sponsor type
Industry
First posted
Jan 28, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It is hypothesized that application at 4-week intervals of the human umbilical cord tissue TTAX01 to the surface of a well debrided, nonhealing venous leg ulcer (VLU) will result in a high proportion of wounds showing complete healing within 12 weeks of initiating therapy. This open label pilot study provides a framework for a larger, controlled study. The purposes for conducting this study are to evaluate the functionality of the protocol and to obtain an estimate of product safety and efficacy when applied according to the protocol instructions, and measured according to the stated endpoints.

Conditions

  • Venous Leg Ulcer

Interventions

  • TTAX01Biological

    TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of Dulbecco's Modified Eagle Medium/Glycerol (1:1) containing Amphotericin B.

  • Profore Compression TherapyOther

    Subjects will utilize the compression system for the duration of the trial, with weekly re-applications of the compression system during study visits

  • Cadexomer Iodine dressingOther

    During the 2-week Screening Run-in period, subjects should be applied cadexomer iodine on the VLU.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete wound healingTime frame: 12-weeks

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • ILD Consulting, Inc.

    Carlsbad, California

  • UCLA Olive View

    Sylmar, California

  • Rosalind Franklin University

    North Chicago, Illinois

  • Advanced Foot & Ankle Center

    Las Vegas, Nevada

  • St Luke's-Roosevelt Hospital Center

    New York, New York

  • Carilion Clinic

    Roanoke, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.